-
Markets
-
Equities
Sustainable finance2025 Euronext ESG Trends ReportRead moreA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesRead moreThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeRead moreInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Funds
-
Fixed Income
European Defence BondsGroupe BPCE lists the first bondRead moreFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Structured Products
-
Derivatives
Where European Government Bonds Meet the FutureFixed Income derivativesRead moreTrade mini bond futures on main European government bonds
-
Commodities
- Overview
- Quotes snapshot
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Delivery & settlement
- Specifications & arrangements
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesRead moreEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Resources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameRead moreJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Nordhealth Achieves EBITDA - CAPEX Breakeven Ahead of Schedule
18 Jul 2024 12:22 CEST
Issuer
Nordhealth AS
Helsinki, Finland - July 18, 2024 - Nordhealth is pleased to announce that it
has achieved EBITDA-CAPEX breakeven in Q2 2024, excluding one-off, non-recurring
items. This milestone, initially projected for Q1 2025 as outlined in the Q4
2023 Investor Presentation on March 5, 2024, and reaffirmed in the 2023 Annual
Report on April 12, 2024, has been reached ahead of schedule.
Preliminary figures indicate that Nordhealth's EBITDA-CAPEX, excluding one-off,
non-recurring items, will be slightly positive in Q2 2024. However, as planned,
the company does not expect to maintain EBITDA-CAPEX breakeven in H2 2024 and
the full year of 2024.
This accelerated improvement is primarily driven by higher-than-forecasted
implementation and recurring revenues in our Veterinary business unit.
Nordhealth continues to anticipate 15-20% growth in recurring revenue in 2024
compared to 2023, calculated at a constant currency rate as of December 31,
2023. Further information on profitability guidance will be provided in our Q2
2024 Investor Presentation on August 20, 2024.
For further information, please contact:
Charles MacBain, Group CEO
charles.macbain@nordhealth.com
+44 75 3903 2200
Mari Orttenvuori, CFO
mari.orttenvuori@nordhealth.com
+358 46 8765 233
About Nordhealth
Nordhealth is a publicly listed, fast-growing cloud-based healthcare SaaS
company on a mission to redefine digital healthcare. We build software that
empowers veterinary and therapy professionals to provide the best possible care
experiences to their patients. Our products serve more than 60,000 veterinary
and therapy professionals across 13,000 in over 40 countries.
Headquartered in Helsinki, Finland, Nordhealth has a solid footprint in the
Nordic region and a growing presence internationally, with over 400 employees
working either remotely or from offices (collaboration hubs). Visit the
company's website at
(https://www.nordhealth.com)nordhealth.com (https://www.nordhealth.com).
More information:
Access the news on Oslo Bors NewsWeb site
Source
Nordhealth AS
Provider
Oslo Børs Newspoint
Company Name
NORDHEALTH AS A-AKSJER
ISIN
NO0011002651
Symbol
NORDH
Market
Euronext Growth